Genome & Company Joins Eli Lilly AI Development Platform
The partnership integrates AI-driven predictive modeling to accelerate the screening of new antibody and molecule candidates.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you believe artificial intelligence will significantly accelerate the discovery of life-saving drugs?
Genome & Company has joined the Eli Lilly drug development platform, Lilly TuneLab, to integrate AI-driven candidate screening. This announced partnership aims to accelerate drug discovery timelines by utilizing Eli Lilly's predictive efficacy and safety models.
Why it matters
The collaboration leverages AI-assisted screening to potentially reduce the time and costs associated with bringing new antibody therapeutics and small-molecule compounds to market. It signals a broader industry shift toward using shared AI infrastructure to de-risk candidate selection early in the development pipeline.
Genome & Company utilizes its proprietary GenoCL platform to isolate candidate substances, which are then assessed by Eli Lilly's AI models. These models predict the development potential of candidates based on historical data regarding drug efficacy and safety.
The players
Genome & Company
A biotechnology firm focused on the development of antibody therapeutics and small-molecule compounds using its proprietary GenoCL screening platform.
Eli Lilly
A multinational pharmaceutical corporation that develops global drug innovation programs and proprietary AI models for candidate screening.
The details
The partnership focuses on refining the drug discovery process by pairing the GenoCL platform—a proprietary system for identifying antibody therapeutics and small-molecule compounds—with the predictive capabilities of the Lilly TuneLab platform. Lilly TuneLab, a component of the broader Lilly Catalyze360 open innovation program, uses AI trained on extensive datasets to simulate and evaluate how candidate molecules might perform. By applying these predictive insights early in the pipeline, the companies aim to filter out non-viable candidates before more expensive development phases occur.
Timeline
October 26, 2026: The partnership between Genome & Company and Eli Lilly was publicly announced.
The Tech Race
This development follows the strategic framework established by the Lilly Catalyze360 open innovation program to accelerate external drug development. The move places Genome & Company among a growing cohort of biotech firms integrating large-scale pharmaceutical AI infrastructure to compress research cycles.
For investors and biotech stakeholders, this collaboration marks a transition toward tech-enabled drug development workflows. While there is no immediate product release for patients, the efficacy of this platform integration will be measured by the speed at which candidate molecules reach clinical trial milestones.
The takeaway
The move underscores the growing reliance on AI-trained predictive models to streamline early-stage pharmaceutical R&D. Stakeholders should monitor the companies' respective technology transfer milestones and future disclosures regarding the first set of candidates screened through this platform.
Further reading
For more on the current landscape of AI-integrated pharmaceutical research, see Biotech.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you believe artificial intelligence will significantly accelerate the discovery of life-saving drugs?
